Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAK-360 Long-term Extension Trial in Central Hypersomnia Conditions
NCT07646678Phase 3Recruiting
- Sponsor
- Takeda
- Start
- Jun 2026
- Primary completion
- Jun 2031
- Countries
- 5
01
Overview
A Phase 3 trial of TAK-360 in idiopathic hypersomnia (IH), narcolepsy type 1 (NT1), narcolepsy type 2 (NT2), sponsored by Takeda. Started Jun 2026; status: recruiting.
02
Drugs
TAK-360
03
Conditions
idiopathic hypersomnia (IH)narcolepsy type 1 (NT1)narcolepsy type 2 (NT2)
Beyond the preview
Go deeper on NCT07646678.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07646678.